ArticleScientific reports2025
The effects of high-altitude hypoxic environment on the pharmacokinetics and respiratory function of remimazolam: an experimental study in rats.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
This study investigated the impact of high-altitude hypoxic environment on the pharmacokinetics and respiratory effects of remimazolam in a rat model. Forty Sprague-Dawley rats were randomly divided into plain and plateau groups, with the plateau group exposed to a simulated altitude of 5,000 m for 72 h prior to drug administration. Pharmacokinetic parameters, respiratory function, and safety profiles were evaluated following intravenous administration of remimazolam. Results showed that high-altitude exposure significantly altered remimazolam pharmacokinetics, with increased maximum plasma concentration (1368.2 ± 227.5 vs. 1025.6 ± 184.3 ng/mL), prolonged elimination half-life (63.5 ± 10.4 vs. 48.6 ± 8.2 min), and reduced clearance (0.89 ± 0.16 vs. 1.26 ± 0.24 L/h/kg) in the plateau group compared to the plain group. The plateau group also exhibited more pronounced respiratory depression, with greater decreases in PaO₂ and oxygen saturation, and higher incidence of adverse reactions. These findings suggest that high-altitude hypoxic environment significantly impacts remimazolam pharmacokinetics and respiratory effects, necessitating careful dose adjustment and monitoring in high-altitude clinical settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.